STOCK TITAN

Jasper Therapeutics (JSPR) SEC Filings, Aug-Sep 2026

JSPR NASDAQ

Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.

The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.

Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) is calling a virtual special stockholder meeting on September 30, 2026 to vote on three capital-structure proposals. The first would authorize the board, any time through December 31, 2026, to implement a reverse stock split of common stock at a ratio between 1‑for‑15 and 1‑for‑35, without changing the 490,000,000 authorized common shares. This is primarily intended to help regain compliance with Nasdaq’s $1.00 minimum bid requirement after a notice received on June 3, 2026; the stock last closed at $0.6864 on September 3, 2026. The second proposal would increase authorized common shares from 490,000,000 to 675,000,000, mainly to ensure enough shares to convert 9,555,390 preferred shares issued in connection with the Kira Pharmaceuticals acquisition and a concurrent financing. As of August 10, 2026, common shares outstanding were 33,274,561. The third proposal would allow adjournment of the meeting to solicit more proxies if needed. The board recommends voting FOR all three proposals and notes that each is considered a “routine” matter for broker voting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
proxy
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) reports that on August 21, 2026 it received a Nasdaq notice that, based on stockholders’ equity reported in its June 30, 2026 Form 10-Q, it no longer meets the $2,500,000 minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market under Rule 5550(b)(1).

The notice has no immediate effect on trading while Jasper remains in compliance with other continued listing standards. The company has 45 days, until October 5, 2026, to submit a compliance plan and may receive up to 180 days from August 21, 2026 to regain compliance if Nasdaq accepts the plan. Jasper currently anticipates seeking stockholder approval to convert outstanding Non-Voting Convertible Preferred Stock at a special stockholder meeting as part of regaining compliance, but states there is no assurance that approvals will be obtained, that Nasdaq will accept its plan, or that it will ultimately maintain its Nasdaq listing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
current report
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (symbol JSPR) is asking stockholders at a virtual special meeting on September 30, 2026 to approve three proposals. The first would amend its certificate of incorporation to allow the board, any time on or before December 31, 2026, to implement a reverse stock split of its common stock at a ratio between 1-for-15 and 1-for-35, without changing the number of authorized common shares.

The board cites a Nasdaq notice received on June 3, 2026 that JSPR’s share price had stayed below the $1.00 minimum bid requirement; the stock closed at $0.716 on August 21, 2026. The company believes a reverse split could help regain compliance, though it may choose not to implement it even if approved.

The second proposal would increase authorized common shares from 490,000,000 to 675,000,000. This is tied to Jasper’s July 16, 2026 acquisition of Kira Pharmaceuticals and a related financing, under which Jasper issued 5,195,009 common shares and 9,555,390 preferred shares, each convertible into 61 common shares, and agreed to sell approximately 4.7 million preferred shares for about $132 million. The extra authorized shares are intended to support full conversion of this preferred stock. The third proposal would permit adjournment of the meeting to solicit more proxies if needed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.30%
Tags
proxy
Rhea-AI Summary

Jasper Therapeutics, Inc. has a significant shareholder group led by Velan Capital Investment Management LP and related entities reporting beneficial ownership of its voting common stock. As of August 17, 2026, Velan Capital and affiliated funds collectively may be deemed to beneficially own 3,363,347 shares, equal to approximately 9.9% of the outstanding shares, including shares underlying certain warrants and options subject to a 9.99% beneficial ownership blocker. The group previously reported on Schedule 13D, but as of this date indicates it no longer holds the securities with a purpose or effect of changing or influencing control of Jasper Therapeutics and is instead reporting on a passive ownership basis consistent with Schedule 13G.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.95%
Tags
ownership
-
Rhea-AI Summary

Jasper Therapeutics reported much lower losses for the quarter ended June 30, 2026 and detailed major strategic steps. For the quarter, operating expenses were about $9.2 million, including research and development of roughly $5.1 million and general and administrative costs of about $4.1 million. Net loss was approximately $2.8 million, compared with $26.7 million in the same quarter of 2025, helped by $6.4 million of total other income, including changes in warrant liability.

As of June 30, 2026, Jasper had $7.3 million in cash and cash equivalents and total assets of about $11.8 million, with stockholders’ equity of $1.4 million. After quarter-end, Jasper closed the acquisition of Kira Pharmaceuticals and completed a concurrent $132 million PIPE financing. Management states that, supported by this financing, it believes it has sufficient capital to fund planned operations through the second half of 2028 while advancing its clinical pipeline, including KP-104, briquilimab, and KP-701.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
current report
-
Rhea-AI Summary

Jasper Therapeutics, Inc. reported a much smaller net loss for the six months ended June 30, 2026 of $3.9 million, compared with $48.0 million a year earlier. Operating expenses fell to $20.2 million from $48.9 million, reflecting prior restructuring, narrower R&D focus and lower general and administrative costs. Results also benefited from $13.6 million of non‑cash income from remeasuring warrant liabilities and a $2.3 million gain from reversing a CIRM grant liability.

Cash, cash equivalents and restricted cash declined to $7.7 million at June 30, 2026 from $29.1 million at year‑end 2025, after $21.5 million of operating cash outflows in the first half. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months, even after considering cost‑control plans.

Subsequent to quarter‑end, Jasper closed the acquisition of Kira Pharmaceuticals and a related private placement of Non‑Voting Convertible Preferred Stock generating $132.0 million of gross proceeds, and entered into a $12.0 million upfront license agreement with Mirador Therapeutics. The company also put in place a $30.0 million contingent value right tied to a potential Priority Review Voucher for briquilimab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.46%
Tags
quarterly report
Rhea-AI Summary

Jasper Therapeutics, Inc., a Delaware biotechnology company, reports a private exempt equity offering under Rule 506(b) of Regulation D. The total amount of equity securities sold is $131,999,611, with $0 remaining to be sold, indicating the offering is fully subscribed. The first sale occurred on July 21, 2026. No finders’ fees are reported, with such expenses stated as $0. The company declines to disclose its revenue or asset size. The issuer is not registered as an investment company and operates in the health care biotechnology industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
other
-
Rhea-AI Summary

Jasper Therapeutics, Inc. reported that director Thomas G. Wiggans received an automatic grant of a stock option covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The option expires on 2036-07-31 and, under the Non-Employee Director Compensation Policy, vests in full on the first anniversary of the 2026-07-31 grant date, subject to his continued board service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
insider
-
Rhea-AI Summary

Jasper Therapeutics director Lucas Svetlana received an automatic grant of stock options covering 7,500 shares of Voting Common Stock. The options were awarded under the Non-Employee Director Compensation Policy at an exercise price of $0.6300 per share, vesting in full on the first anniversary of the grant, and leave Lucas holding 7,500 derivative securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
insider
Rhea-AI Summary

Crutcher Patrick J reported acquisition or exercise transactions in this Form 4 filing.

Jasper Therapeutics, Inc. reported that director Patrick J. Crutcher received a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, exercisable at $0.63 per share. The option vests in full one year after grant, subject to continued service, and expires July 31, 2036, leaving him holding 7,500 options directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
insider

FAQ

How many Jasper Therapeutics (JSPR) SEC filings are available on StockTitan?

StockTitan tracks 89 SEC filings for Jasper Therapeutics (JSPR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Jasper Therapeutics (JSPR)?

The most recent SEC filing for Jasper Therapeutics (JSPR) was filed on November 16, 2026.